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Acute and chronic wounds affect millions of people around the world, imposing a growing financial burden on
patients and hospitals. Despite the application of current wound management strategies, the physiological
healing process is disrupted in many cases, resulting in impaired wound healing. Therefore, more efficient and
easy-to-use treatment modalities are needed. In this study, we demonstrate the benefit of in vivo printed, growth
factor-eluting adhesive scaffolds for the treatment of full-thickness wounds in a porcine model. A custom-made
handheld printer is implemented to finely print gelatin-methacryloyl (GelMA) hydrogel containing vascular
endothelial growth factor (VEGF) into the wounds. In vitro and in vivo results show that the in situ GelMA
crosslinking induces a strong scaffold adhesion and enables printing on curved surfaces of wet tissues, without
the need for any sutures. The scaffold is further shown to offer a sustained release of VEGF, enhancing the
migration of endothelial cells in vitro. Histological analyses demonstrate that the administration of the VEGFeluting GelMA scaffolds that remain adherent to the wound bed significantly improves the quality of healing
in porcine wounds. The introduced in vivo printing strategy for wound healing applications is translational and
convenient to use in any place, such as an operating room, and does not require expensive bioprinters or imaging
modalities.

1. Introduction
Skin integrity is instrumental to protect the body from the external
environment, regulate body temperature, and prevent dehydration [1].
Therefore, the ability of the body to ensure skin integrity, by healing
wounds, is an essential physiological process. Wound healing consists of
three overlapping phases: inflammation, proliferation, and remodeling
[2,3]. However, wounds may, pathologically, fail to progress through
the normal healing pathway [4]. These wounds either under-heal and
become chronic or over-heal and form excess fibrous connective tissue
that results in scarring [5,6]. Despite the utilization of current wound
treatments, compromised wound healing affects nearly 8 million people
in the United States annually, and incur staggering healthcare costs [7].

Novel and more efficient treatment modalities are needed to treat pa
tients with poorly healing wounds [8].
While autografts are considered the “gold standard” approach for the
treatment of severe skin injuries, their application is limited by variable
tissue integration, incomplete functional recovery, and donor site
morbidity [9]. Recent developments in tissue engineering and drug
delivery technologies have presented promising alternative approaches,
either alone or combined with traditional wound treatments [10–13].
Different scaffolding biomaterials, such as hydrogels, have been imple
mented as artificial grafts to improve wound closure [9,10]. Hydrogels
are interesting candidates as dermal substitutes, due to their similarity
to native extracellular matrix, tunable mechanical and chemical prop
erties, and their cell permissibility [14–17]. Furthermore, many studies
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suggest that the application of hydrogels, with controlled release of
bioactive factors, using active or passive delivery strategies, can improve
wound healing [18,19]. Controlled, local release of drugs from hydro
gels can boost the healing process while preventing a systemic drug
toxicity [20,21].
Injectable hydrogels with in situ gelation and prefabricated hydrogel
grafts demonstrated promising outcomes for tissue regeneration [22].
However, these scaffolds suffer from poor tissue integration specifically
when dealing with open wounds, due to the irregular shape of the defect
and limited scaffold fidelity or adhesion, which necessitates fixation
modalities. Creating hydrogel grafts with complex geometry and proper
structural stability into open defects on curved surfaces requires an ac
curate control on the deposition and crosslinking of the bioink. 3D
bioprinting has been implemented for the fabrication of more complex
scaffolds to be implanted into the wound site [23,24]. While bioprinting
strategies can indeed offer an automated fabrication of complex scaf
folds, they have several drawbacks. First, these systems require highly
complicated expensive facilities for imaging the defects, analyzing its
shape and size, and printing the corresponding scaffold [25]. Moreover,
the 3D printed hydrogel scaffolds are not typically adhesive [26]. This
necessitates the implementation of fixation modalities. Even still, the
non-adherent scaffolds are susceptible to detach during motion, which
will impair their tissue integration. In addition, most currently available
stationary bioprinters are unable to print scaffolds on curved surfaces
[25,27,28].
Recently, there has been a new trend in directly printing scaffolding
materials into the defect site [25]. In situ bioprinting minimizes the
preparation time of scaffolds, promotes rapid wound closure, and limits
fibrosis [29–31]. Two main in situ bioprinting strategies have been
developed in regenerative medicine: robotic in situ printing [31] and
handheld in situ printing [32]. Although in situ printing using a robotic
system can be highly accurate and reliable, it requires complex and
expensive facilities, imaging tools, and computer-aided techniques for
analysis and reconstruction of defects with irregular shapes. Recently
developed, handheld bioprinters minimize the complexity of in situ
printing by eliminating the requirement of imaging modalities, while
allowing the printing of irregular shape scaffolds on curved surfaces
[32–37]. Using this strategy, the defect structure can be inspected and
scaffolding material can directly be deposited into the wound, con
forming to any shape or topography. In a prominent study, a handheld
printer was developed that could deposit hydrogel strips onto the wound
surface [32,38]. A two-barrel handheld extruder was used to simulta
neously extrude scaffolding material and its crosslinker through a
microfluidic printing head. While the printing of wide hydrogel strips
allows for rapid wound coverage, it is challenging to conform to irreg
ular shapes and crevices. Furthermore, the need for application of a
crosslinking reagent can make the in situ printing more challenging and
less biocompatible. A special attention therefore is required to be
devoted for the selection of bioink for in situ printing in wound healing
applications. In addition to printability and biocompatibility, the bioink
needs to establish a strong adhesion upon crosslinking. This prevents the
detachment of the graft due to the body movement and allows rapid
tissue engraftment [33]. Additionally, bioinks can be supplemented with
regenerative factors, specifically to regulate impaired physiological
processes post major injuries [39,40].
In this study, a custom-made and easy-to-use handheld bioprinter is
utilized to apply gelatin-methacryloyl (GelMA) hydrogel containing
vascular endothelial growth factor (VEGF) to promote tissue regenera
tion and improve wound healing. The application of fine nozzle in the
handheld bioprinter enables accurate filling of defects with irregular
shapes while the capability of tuning the flow rate in a wide range
provides the control over the speed of printing for small and large size
wounds. GelMA was selected to address the mentioned requirements of
printability, biocompatibility, and mechanical properties. It further al
lows the sustained release of encapsulated molecules, such as growth

factors, following photocrosslinking. Given the importance of proper
vascularization for improved wound healing [41], VEGF was selected as
the therapeutic factor loaded into the GelMA scaffold. VEGF can
enhance the activity of endothelial cells and induces angiogenesis [4].
The proper vascularization can ensure sufficient tissue oxygenation and
metabolic support, and a regulated physiological responses to the dy
namic wound environment [41]. While VEGF-loaded biomaterials have
been previously utilized to improve wound healing [42,43], the aim of
this study is to develop and evaluate the translational feasibility of an in
vivo printing strategy, for timely treatment of wounds with a
VEGF-loaded bioink. In the first phase of this study, the properties of
VEGF containing GelMA hydrogels and its influence on the behavior of
endothelial cells were studied and optimized in vitro. Subsequently, in
the second phase, the effect of in vivo printing of this scaffold on the
healing and its translational feasibility were investigated in a
full-thickness porcine wound healing model.
2. Results and discussion
2.1. A custom-made handheld bioprinter enables in situ printing
Handheld bioprinters provide an opportunity for direct printing of a
scaffold onto a wound surface. In this study, we used in situ printing of
VEGF-releasing scaffolds to improve wound healing (schematic in
Fig. 1A). A custom-made, partially-automated handheld bioprinter was
fabricated, with an embedded ultraviolet (UV) light, which enables in
situ crosslinking of the photo-polymerizable bioinks (Fig. 1B). The
printer utilizes an extrusion system based on the transfer of rotational
motion of an electric motor into linear motion, pushing the plunger of a
syringe carrying the bioink. The device enables a stable plunger motion
with a variability less than 5% of the set value. The handheld printer is
able to quickly and easily print filaments into any shape (Fig. 1C). The
deposition rate of the device could be controlled in a wide range of 4 μL/
s to 18 μL/s, suitable for treatment of small and large defects (Fig. 1D). A
lower flowrate improves the control over the shape and architecture of
the deposited scaffold, while the higher flowrate allows rapid printing
for timely covering of the large wound surfaces. Furthermore, the res
olution of the bioprinting could be controlled by tuning the diameter of
deposited filament below the millimeter scales through changing the
traveling speed of the printing (Fig. 1E; details are provided in the
Experimental Section). It can be seen that the diameter of the filament
reduced by increasing the moving speed (hand movement speed) at a
constant extrusion rate.
The in situ printing strategy significantly promotes the flexibility of
the treatment by allowing the scaffolds deposition onto irregular-shaped
defects, on the curved surfaces, and even on moving body parts. In situ
crosslinking can potentially result in the enhanced adhesion of the
scaffold, minimizing the requirement of fixation modalities for the
implanted scaffold [33]. The adhesion of the scaffold to the native
remnant tissue is an important feature considering the challenges of
implanting in vitro fabricated soft scaffolds into the defect [33,44]. It
should be noted that the integrated light used for in situ crosslinking is a
395 nm wavelength light, at the border of UV-A and visible light spec
trums, which have been widely used in the medical applications for
biopolymer crosslinking. It has been previously shown that exposure to
such low intensity light for short periods of time has negligible detri
mental effect on cellular behavior, even at lower ranges of wavelengths
in UV-A spectrum [45–47].
While the repeatability of handheld devices is expected to be lower
than conventional automated 3D printers, they offer sufficient resolu
tion to allow precise filling of the defects in tissues with irregular shapes
such as injured skin. Implementing this device, we demonstrated suc
cessful in vivo printing of growth factor loaded GelMA within the wound
site.
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Fig. 1. In vivo printing of growth factoreluting hydrogel for wound healing appli
cations. (A) Schematic representation of the
in vivo printing strategy. GelMA precursor
supplemented with VEGF is extruded using a
handheld printer and photo-crosslinked in
situ. This approach enables the treatment of
a wound with irregular shapes and on
curved surfaces. In situ crosslinking offers
the adhesion of the scaffold to the tissue and
eliminates the requirement of fixation mo
dalities. The released VEGF promotes
angiogenesis in the wound bed and conse
quently enhances the quality and rate of
wound healing. (B) The portable handheld
printer used in this study. The device is a
partially automated system allowing the
adjustment of deposition rate and in situ
photo-crosslinking with an integrated UV
light. (C) Printing of hydrogel scaffolds for
precise deposition of the bioink using the
handheld printer. (D) The deposition rate of
the device can be adjusted in a continuous
manner, in the range of 4 μL/s to 18 μL/s (n
= 4 was used for each point). (E) The
diameter of the deposited filaments can be
adjusted based on the printing speed and the
applied flow rate. Inset shows the hydrogel
filaments printed with different sizes. Here,
a 22-gauge tapered nozzle was used.

2.2. Characterization of GelMA ink for in situ printing

response to compressive loads. Three different concentrations were
evaluated: 6%, 9% and 12% (w/v). A compression modulus of 1.2 ± 0.2
kPa (mean ± SD), 4.1 ± 0.2 kPa, and 10.6 ± 0.8 kPa was observed for
6%, 9% and 12% (w/v) GelMA scaffolds, respectively. We also evaluated
the adhesion strength of in situ crosslinked GelMA to porcine skin. Using
a setup depicted in Fig. 2B, the shear adhesion strength of the printed
hydrogel to porcine skin was assessed. An adhesion strength of 3.7 ± 1,
6.3 ± 0.5 and 10.3 ± 2.5 kPa was obtained for 6%, 9%, and 12% GelMA,
respectively. These adhesion strengths are close to the shear strength of
the material itself, as demonstrated by the failure of most samples in the
bulk GelMA rather than the adhesion interface with the skin (Fig. 2C).
Scanning electron microscopy (SEM) evaluations further confirmed
good binding between the GelMA and skin microstructures (Fig. 2D).
GelMA has been implemented as a bioadhesive for regenerative ap
plications [56,57]. The strong GelMA-tissue adhesion upon in situ
crosslinking is attributed to physical interlocking, the generation of free
radicals during photocrosslinking that forms covalent bonds, and
hydrogen bonds formed due to the presence of free hydroxyl groups in
the hydrogel structure [57,58]. As demonstrated by our results (Fig. 2B
and C), the adhesion strength of the in situ crosslinked GelMA is close to
the shear strength of the material, and therefore can be modulated with
hydrogel concentration. Through manipulation of the GelMA

An ideal bioink should be printable, supportive for cellular ingrowth,
biodegradable, and allow for cell attachment [47,48]. The bioink must
offer a suitable viscosity to enable controllable printing with excellent
shape fidelity [49]. In addition, the mechanical properties of the cross
linked scaffold need to be tuned for regeneration applications [50].
Specifically for wound healing applications, a soft scaffold, similar to a
temporary fibrin network, is preferred [51]. Softer gels, which are easier
to be remodeled by nascent cells, better support cell infiltration and
spreading [52,53].
GelMA is reported to serve as a suitable scaffolding hydrogel due to
the similarity of its structure to native ECM, the presence of cell
attachment sites and degradable sequences in its structure, easy photocrosslinking, and controllability over its mechanical properties [45,47,
54,55]. Therefore, GelMA was selected in this study and its concentra
tion was optimized to offer decent printability, suitable tissue adhesion,
and support cellular function (Fig. 2). Fig. 2A shows the results of the
mechanical properties evaluation based on a compression test. The
scaffolds were being printed at the stretched state of the native tissue
where tissue movements are expected to compress the scaffolds.
Therefore, the mechanical properties of the hydrogels were measured in
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Fig. 2. Characterization of the printing
bioink for wound healing application. (A)
Evaluating the elastic modulus of GelMA
hydrogel with different concentrations
through compression tests. While a softer
hydrogel is preferred for enhanced cell
spreading and migration, 9% GelMA was
selected as the bioink formulation in this
study due to the limited printability of ma
terial having lower concentrations. (B) The
assessment of the in situ crosslinked GelMA
adhesion strength to skin using a modified
shear test. The setup used for shear tests is
schematically shown. (C) A representative
sample from the shear tests demonstrating
that the failure occurred from the bulk
GelMA rather than adhesion interface with
the skin. (D) SEM cross-section micrograph
of the GelMA/pig skin interface demon
strating a proper binding between two mi
crostructures. GelMA is the top brighter
region in the image while the pig skin is the
darker bottom area. (E) A magnified SEM
micrograph showing the internal porous
structure of GelMA hydrogel. (F) Release
assessment studies demonstrating the capa
bility of the hydrogel network to offer a
sustained release of VEGF molecules. The
setup used in this study is shown in (i), while
the VEGF release profile is shown in (ii). n =
6 in mechanical properties evaluation and n
= 4 for release experiments were utilized.

concentration and crosslinking time, previous studies have demon
strated that the adhesion strength could be tuned to be comparable to
that of commercially available tissue adhesives but with superior
biocompatibility and cell permissibility [56,57]. In this study, GelMA is
implemented as a temporary scaffold releasing angiogenic factors for
improved wound healing. Therefore, a softer hydrogel with higher cell
permissibility is preferred, while the adhesion properties close to the
material strength is enough for our in vivo printing and subsequent tissue
integration.
For in situ printing using our device, the pre-warmed bioink at 37 ◦ C
was first loaded into the syringe followed by its incubation at room
temperature for 5–10 min to allow its partial gelation as a result of
temperature reduction [53]. The partial gelation increases the viscosity
of the bioink and allows easy deposition using the handheld device.
However, due to the low concentration of 6% GelMA in our study, its
printability and final shape fidelity were inadequate for in situ printing
applications. Higher concentrations of the GelMA (9% and 12%) were
further examined (Fig. S1), and the 9% solution was selected to be used
in the animal study due to its better printability and lower stiffness. As
mentioned before, lower stiffness is expected to expedite cell infiltration
and spreading inside the GelMA scaffolds [54].
The internal microstructure of applied GelMA in this study was
further evaluated using SEM (Fig. 2E). A porous hydrogel structure, with
an average pore size of 9.57 μm was detected using the SEM analysis of
the lyophilized hydrogel. While the SEM analysis upon lyophilization is
widely used for evaluating the internal microstructure of the GelMA
[45], critical point drying was also performed to further confirm the
porous microstructure of the implemented GelMA hydrogel, not affected
by the freeze-drying step (Fig. S2). Such porous structures can help cell
spreading and migration, and enables the rapid transport of nutrients,
oxygen, and wastes through the structure, all necessary for proper
regeneration [16]. The porous nature of the scaffolds further enables the

sustained release of therapeutics [40,59]. The results of our release
studies demonstrated the capability of the structure to preserve VEGF
molecules and release them over time (Fig. 2F). The cumulative release
profile demonstrate that a gradual long-term release can be obtained up
to several days. This significantly enhances the local availability of the
therapeutics in the wound environment.
It is also important that the released VEGF from the hydrogel remains
intact over time in a physiological temperature. To ensure the integrity
of the growth factor released from the GelMA, western blot analysis was
performed on the samples collected at day 7 of the release study. The
results demonstrated that the majority of the released VEGF remains
intact, with an apparent molecular weight close to 30 kDa, similar to the
reported value by the provider (Fig. S3).
2.3. Released VEGF promotes endothelial cell migration in vitro
Proper vascularization of the wound bed, ensures sufficient meta
bolic support throughout the healing process, the proper immune
response to potential infection, and a balanced infiltration of the cells
associated with regeneration [3]. Sustained release of VEGF is used in
this study for the stimulation of the endothelial cells and induction of
angiogenesis. To ensure the effectiveness of the released VEGF from the
printed scaffold on enhancing the migration of endothelial cells, prior to
animal studies, a standard in vitro scratch assay [40] was carried out
(Fig. 3). A confluent monolayer of human umbilical vein endothelial
cells (HUVECs) was scratched and then treated with VEGF released from
GelMA to evaluate its effect on cell migration (Fig. 3A). Four different
groups underwent the scratch assay: (i) a negative control group, in
which the scratch did not receive any treatment, (ii) a blank GelMA
group, (iii) a VEGF-eluting GelMA group, and (iv) a positive control
group treated directly with VEGF. Fig. 3B and C demonstrate the qual
itative and quantitative outcomes. Over time, the cells, which were
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Fig. 3. The effect of VEGF released from the
GelMA network on the functionality of
HUVECs. (A) A scratch assay was designed
to examine the effectiveness of the release
strategy on the migration of endothelial
cells. Following the formation of a confluent
monolayer of HUVECs, a scratch was made
and treated with different conditions placed
into cell culture media. (B) Quantitative
assessment of the scratch assay results. Four
different groups were compared to under
stand the effect of GelMA releasing VEGF on
the activity of endothelial cells. The results
confirm the beneficial effect of strategy for
enhancing cellular activity. n = 3 was used
at each time-point. (C) Representative im
ages of the scratch area over time.

confluent in the vicinity of the gap, migrate to the available space
generated by the scratch. The comparison between the positive and
negative control groups confirmed that the migration capability of the
HUVECs can be improved by supplementation of VEGF. Furthermore, by
comparing the GelMA + VEGF group with the GelMA and negative
control, it is demonstrated that GelMA alone did not have a positive
effect on cell migration while the released VEGF from the GelMA
network in the GelMA + VEGF group could significantly enhance the
migration of HUVECs. These data suggest that the encapsulated VEGF
remained functional throughout the scaffold fabrication process.

2.4.1. Macroscopic evaluation of wound healing
Macroscopic wound closure was evaluated on days 7 and 14 (Fig. 4).
Representative photographs (Fig. 4A) and the quantitative results
(Fig. 4B–D) showed that the wounds in all groups had closed relatively
well, which can be due to the use of healthy young pigs in the study. The
analysis showed that by day 7, the wounds were more than 60% smaller
in comparison to the original wound area. On day 14 post-surgery, the
remaining wounds were similarly closed compared to the original size in
all groups. Although no statistically significant differences were
observed in the macroscopic wound closure, a significant difference was
observed in the wound healing mechanism. Similar to humans, porcine
wounds normally heal by formation of granulation tissue and reepithelialization, as well as contraction [61,62].
Wound contraction was measured from the macroscopic photos
using the tattooed wound margins (Fig. 4B). The results showed that by
day 14, the wounds treated with the bioprinted GelMA containing VEGF
had minimally contracted (18 ± 4%), which was significantly less than
blank GelMA (30 ± 2%), Topical VEGF (31 ± 4%) and control groups
(46 ± 3%) (Fig. 4E). Blank GelMA treated also exhibit significantly less
contraction than non-treated wounds. While contraction is a reparative
mechanism following full-thickness skin injury, excessive contraction
can lead to hypertrophic scarring, poor cosmetic outcomes, and limit the
functionality of the healed tissue [5,63]. Furthermore, the mechanical
properties of the contracted scarred skin is typically weaker than the
original tissue, increasing the possibility of wound reopening [64]. As
such, novel therapeutics aim to limit the contracture rate [65].
Commercially available dermal regenerative matrixes and cellulose
hydrogels have shown to modestly decrease wound contracture rate and
promote functional recovery following wound creation, but these sys
tems require cutting and suturing to conform to wound edges [66].
These matrixes should also be secured in place by suturing.

2.4. In vivo printing of VEGF-eluting GelMA scaffolds improves wound
healing in a porcine model
In order to evaluate the translational feasibility of the in vivo printing
strategy and its efficacy for wound healing applications, porcine fullthickness wound model was implemented in this study. Fig. S4 in
dicates the workflow of the animal studies in this work. Circular dorsal
wounds were created and the borders of the wounds were tattooed. The
wounds were randomly divided into four different treatment groups: i)
no treatment (as a negative control), ii) topical VEGF delivery, iii) in situ
printed, blank GelMA scaffolds, and iv) in situ printed GelMA scaffolds
supplemented with VEGF. We implemented a previously verified VEGF
dosage required for induction of vascularization, and consequent
improvement in wound healing, in small and large animals (see Exper
imental Section for more details) [4,60]. Additionally, the optimized
concentration of GelMA (9%) was used for the treatments and printing
was performed at 5 μL/s. Wound healing was evaluated at 7 and 14 days
post injury. All of the printed hydrogels were adhered to the surrounding
tissue after printing and during wound inspections throughout the study.
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Fig. 4. Macroscopic wound closure. (A) Representative pictures of the wounds administrated with different treatments on day 7 and day 14 post surgery. (B)
Schematic illustration of the method for quantification of wound closure and contraction. Quantitative evaluation of macroscopic wound closure on (C) day 7 and (D)
day 14 post surgery. (E) Wound contraction relative to the original wound size. While no statistically significant difference was observed in macroscopic wound
closure, the wounds treated by in vivo printing of GelMA releasing VEGF had contracted significantly less than the other groups. In addition, the blank GelMA treated
wounds exhibit significantly less contraction than the non-treated wounds. n = 6 used for all quantifications.

2.4.2. Microscopic evaluation of wound healing
Microscopic analysis of wound healing further supported a signifi
cant improvement in the wound healing quality following in vivo
printing of VEGF-eluting GelMA scaffold. Fig. 5 includes representative
pictures of the wound bed stained with hematoxylin and eosin (H&E,
Fig. 5A–C), and their quantitative characterization (Fig. 5D–I). A higher
level of wound re-epithelialization and granulation tissue was observed
as a result of in vivo printing of VEGF-eluting GelMA scaffolds compared
to the other groups, though, most of the wounds were relatively well reepithelialized and granulated after 14 days, in all groups (Fig. 5D, F).
The ratio of total scar connective tissue area to the area of underlying
dermis was measured to obtain scar elevation index (SEI) of each wound
(SEI=(S1+S2)/S1 shown in Fig. S5) [67]. A SEI of 1 is indicative of
minimal scarring, while a higher number represents pathologically
increased scarring. In accordance to the macroscopic wound healing
results, the SEI was significantly less in the wounds treated with in situ
printing of VEGF-eluting GelMA (Fig. 5F). The SEI in the wounds treated
with VEGF-eluting GelMA was (1.09 ± 0.01), which was significantly
less than the amount after treatment with blank GelMA (1.21 ± 0.05),
topical VEGF treatment (1.24 ± 0.02), and non-treated wounds (1.31 ±
0.06).
The regenerated epithelium was further evaluated by quantifying
epidermal thickness and number of rete ridges. Thickness of the neo
epidermis in the wounds treated with VEGF-eluting GelMA scaffolds
(165 ± 28 μm) was significantly increased in comparison to the blank
GelMA (130 ± 14 μm), topical VEGF (95 ± 13 μm), and non-treated
wounds (85 ± 7 μm) (Fig. 5B and G). A similar trend was observed in
the number of rete ridges in the neoepidermis. The number of rete ridges
in the VEGF-eluting GelMA (9.32 ± 1.37) was higher compared to the

wounds treated with blank GelMA (4.54 ± 1.16), topical VEGF (6.86 ±
0.52), and non-treated wounds (4.69 ± 0.98). The differences between
the VEGF-eluting GelMA, topical VEGF, and non-treated wounds were
statistically significant (Fig. 5B and H). Similarly, other studies have
shown an optimal wound environment results in thicker epidermis and
denser rete ridge formation [68,69].
Finally, the degree of inflammation was studied by analyzing the
H&E stained wound sections for infiltration of inflammatory cells to the
wound bed. The results demonstrated that while inflammation was
present in all wounds, the VEGF-eluting GelMA treated wounds con
tained the fewest number of inflammatory cells. The differences be
tween the GelMA with VEGF and the VEGF in PBS and non-treated
wounds were statistically significant (Fig. 5C and I). Previous studies
suggested that an optimal wound healing environment results in less
inflammation, which is consistent with the present study [70,71].
It has been reported that VEGF is important for skin wound healing,
playing a key role in collagen deposition, angiogenesis, granulation
tissue formation and epithelization [72], our results demonstrate that
topical and abrupt administration of VEGF alone does not significantly
improve the re-epithelialization and granulation. This finding aligns
with pertinent literature suggesting the importance of VEGF bioavail
ability throughout the wound healing [4,21]. The concentration of
VEGF delivered through a burst release in the wound bed can be quickly
decreased due to high fluid turnover in the wound area, considering the
low penetration rate of VEGF topically administered [4,21].
Quality of healing analyses demonstrated that the in vivo printing of
GelMA containing VEGF treatment resulted in better skin regeneration
after wounding. The results showed that wound contraction and degree
of hypertrophy were significantly reduced in the GelMA containing
301
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Fig. 5. Microscopic evaluation of wound healing quality. (A–C) Representative histology pictures of the wound area on day 14 post surgery. The whole wound area is
shown in (A), while the epidermis and wound bed are shown in (B) and (C), respectively. Different groups are the wounds treated with (i) in vivo printed GelMA
containing VEGF (GelMA + VEGF printing), (ii) in vivo printed blank GelMA (GelMA printing), (iii) BPS containing VEGF administrated topically (topical VEGF), and
(iv) wounds left untreated (non-treated). A thicker epithelial layer, more rete ridges, and lower amount of infiltrative cells in the wound bed demonstrates a
significantly higher quality of healing in the wounds treated GelMA + VEGF printing. (D–I) Quantitate analysis of wound healing quality. (D) Wound reepithelialization, calculated based on the area of new epithelium over total wound area. Highest amount of re-epithelialization was observed in the wounds
treated with GelMA + VEGF. (E) Amount of granulation tissue. The GelMA + VEGF treated wounds had the largest area of granulation tissue. (F) Scar elevation index
(SEI), calculated based on the total area of the healed skin over the area of normal skin below the buildup hypertrophic scarring. The wounds treated with GelMA +
VEGF demonstrated significantly less scarring compared to the other groups. (G) Epidermal thickness. The thickness of epidermis was increased in the wounds treated
with the GelMA + VEGF. (H) Rete ridges. The number of rete ridges in the GelMA + VEGF group was significantly higher compared to the non-treated and VEGF
treated wounds. (I) Inflammation. The degree of inflammation was studied by analyzing the H&E stained wound sections for infiltration of inflammatory cells to the
wound bed (Representative figures are shown in (C)). The inflammation was present in all wounds while wounds treated with GelMA + VEGF contained the smallest
number of inflammatory cells. n = 6 was considered for quantifications.

VEGF treated wounds. Wound contraction, a process where differenti
ated fibroblasts called myofibroblasts close the injured area by pulling
the wound edges together, is an important part of normal wound heal
ing. However, if the contraction is excessive and prolonged, it leads to
scarring which can have a significant impact on the quality of life
especially if the function and appearance of healed tissue are affected
[73]. Currently, there is no established therapy to prevent excessive
contraction and scarring, although novel tissue engineering approaches
have shown some promise [63]. Contrary to our results, others have
shown that VEGF may promote scar formation in the skin, although the
mechanisms by which this happens is unclear [74]. The contradictory
results may be due to differences in approach for drug delivery, as
suggested previously [21]. Controlled spatiotemporal drug distribution
can significantly affect the outcomes of growth factor therapies. In the
present study, scaffold-mediated sustained VEGF delivery promotes
wound healing.
Although less effective than GelMA containing VEGF bioink, the in
vivo printing of blank GelMA also significantly reduced the contraction
compared to the non-treated wounds. Previously, it has been shown that
a moist wound environment significantly reduces scar formation and
that hydrogel treatment might also prevent wound contraction [65,69].
In porcine full-thickness wounds, it was shown that application of a
nanocellulose hydrogel prevented wound contraction as well as sec
ondary contraction of a meshed split-thickness skin graft (STSG). Yet, no
mechanism how this happens has been presented [65]. Here, in addition
to sustaining the release rate, adhered GelMA can modulate the wound
moisture, provide a scaffold for cell migration and ingrowth, and
temporarily protect the wound bed before complete healing of the
wound.
Immunohistochemical analysis further confirmed the benefit of in
vivo printing of VEGF-eluting GelMA scaffolds on the angiogenesis and
therefore the quality of wound healing (Fig. 6). To evaluate the amount
of angiogenesis, the level of von Willebrand Factor (vWF), a protein
highly expressed in endothelium, was measured in the wound bed
(Fig. 6A). Qualitative (Fig. 6B and C) and quantitative outcomes
demonstrated a significant increase in wound bed vascularization,
within the depth of granulation tissue, as a result of in vivo printing of
GelMA supplemented with VEGF. A sustained release of VEGF from the
GelMA scaffold ensures the local availability of the VEGF throughout the
wound healing process, which induces angiogenesis and therefore offers
more advanced healing with minimum subsequent scarring. Note
worthy, the topical delivery of VEGF was clearly less effective, high
lighting the importance of sustained delivery in the effectiveness of
drugs and growth factors in wound healing (Fig. 6C). Additionally,
immunostaning against cluster of differentiation 3 (CD3), a protein
highly expressed on the T-cells, demonstrated insignificant immune
response to the proposed treatment (Fig. S6). VEGF delivery was not
expected to offer anti-inflammatory effect, specially in the acute and
non-chronically inflamed wound model used here. However, the
implemented scaffolding material did not lead to increase in the level of
CD3 positive cells. While a statistically significant difference was not
observed between the groups, there was a trend toward reduced immune

Fig. 6. Immunohistochemical analysis of angiogenesis in the wound bed on day
14 post surgery. The wound bed was examined for the expression of von Wil
lebrand Factor (vWF). (A) Representative images of wound bed angiogenesis in
non-treated wounds compared to those treated with BPS containing VEGF
administrated topically (topical VEGF), in vivo printed blank GelMA (GelMA
printing), and in vivo printed GelMA containing VEGF (GelMA + VEGF print
ing). The brown color indicates the presence of vWF. (B) Quantitative results of
wound bed angiogenesis through measurement of vWF signal in different
wounds (n = 6).
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response in the wounds treated with in vivo printing of VEGF-eluting
GelMA hydrogel, confirming the histological evaluations.

Electronics were embedded within the housing and included a contin
uously variable speed controller (P160KN–0FC18C2K5, Digi-Key),
directional toggle (3220, Adafruit), and photocrosslinking system. An
electronic motor (Pololu) enabled extrusion of syringes filled with pre
cursor hydrogels. The rotational motion of the motor was transferred to
linear motion using a leadscrew. The linear motion was controlled by
guiding shafts, enabling the reliable extrusion of the syringe plunger
loaded into the device. A chargeable battery (2500 mAh, GTF) and
power conservation mode were utilized to enable several hours of
continuous operation. The crosslinking system was positioned 45 mm
away from the extrusion nozzle tip and used a 1 W Blue light LED (395
nm wavelength, CH_Town Electronic) for photopolymerization.
The characterization of the printing parameters was perform through
measurement of generated flowrates and calculation of the corre
sponding printing speed and filament diameter. A 9% GelMA was
extruded through a gauge 22 conical nozzle to measure the flowrates in
different motor power levels. The printing speed and corresponding
filament diameter was then calculated and graphed for different
flowrates.

3. Conclusions
In conclusion, the hand-held 3D bioprinter has a great potential to
deliver novel but also available and clinically valuable treatments for
wound healing. The present study demonstrated successful in vitro and in
vivo bioprinting of VEGF-loaded GelMA hydrogel. In the first phase of
the study, the hydrogel characteristics were optimized in vitro to offer
good printability, suitable tissue adhesion, and favorable environment
for cellular function. Subsequently, the VEGF containing GelMA
hydrogel was applied into full-thickness porcine wounds using the handheld 3D bioprinter and its effects on wound closure and quality of
healing were studied. It was observed that bioprinting of the GelMA
hydrogel into the wounds was convenient and enabled rapid wound
coverage. The application of the developed handheld printer enables
printing into complex, irregularly shaped defects, while in situ cross
linking mechanism ensures the bioink is contained within the defect
with homogeneous distribution over the wound area, particularly when
printing onto curved defects. Furthermore, the strategy allows printing
of the hydrogel to conform to the crevices and small corners of the
wound, which enhances the hydrogel-tissue adhesion and subsequent
integration. The results demonstrated that although no differences in
wound closure were seen, the VEGF containing GelMA hydrogel
increased the quality of healing in terms of less wound contraction,
reduced scar formation and enhanced neoepidermis formation in com
parison to control treatments. Interestingly, in vivo printing of blank
GelMA as well as topical VEGF administration demonstrated limited
effects on the wound healing quality, whereas the sustained release of
VEGF from an in vivo printed scaffold with a simple but robust handheld
printer could significantly enhance the wound bed angiogenesis and
resulted in more advanced healing. While in vivo printed scaffolds
clearly showed significant advantages in wound healing quality at day
14, additional studies that would investigate the impact of this treat
ment during all the different phases of wound healing are needed to
comprehensively demonstrate the efficacy. Shorter studies are needed to
assess the effect on inflammation, and longer term experiments are
needed to assess the scarring after complete wound closure.

4.3. Bioink preparation
To prepare the bioink, lyophilized GelMA was dissolved in prewarmed DPBS with desired concentration, followed by addition of a
50X LAP solution (3.35% w/v in DPBS) with a 50:1 volumetric ratio. The
VEGF was then supplemented and the solution was mixed by pipetting
up and down to ensure a uniform distribution of LAP and VEGF
throughout the hydrogel precursor. The preparation of the bioink was
performed under a biosafety hood, using sterile reagents and materials.
To ensure sterility, the bioink was preheated and filtered using syringe
filters (0.22 μm pore size) into a 50 mL centrifuge tube and kept in warm
bath (37 ◦ C) before the experiments.
4.4. Mechanical characterization of GelMA ink
Compression tests were performed to evaluate the elastic modulus of
the GelMA having different concentrations, as previously described
[33]. A molded cylindrical hydrogel structure with a 10-mm diameter
and 4.5 mm height was used as the sample for compression tests. A male
master mold was first fabricated with corresponding dimensions using
SLA 3D printing (ANYCUBIC, Photon S), followed by casting a PDMS
female mold on top of it. Subsequently, a GelMA solution supplemented
with 0.067% (w/v) LAP was filled inside the PDMS mold, capped with a
charged glass slide (Fisher Scientific, Cat: 99-910-01) and
photo-crosslinked through the slide using a UV light (Jowbeam) for 20 s
from a distance of 4 cm. The hydrogel cylinder was then removed from
the mold and placed between compression plates mounted on a me
chanical testing device (Model: 3220-TA Series III, TA Instruments), as
shown in Fig. 3A. A compression rate of 0.1 mm/s was then applied and
the elastic modulus was calculated from the slope of a fitted line inter
polating the stress-strain data up to 10% strain.

4. Experimental Section
4.1. Materials
GelMA with medium degree of methacrylation was purchased from
Allevi (Cat: GMA) while Lithium phenyl-2,4,6-trimethylbenzoyl
phosphinate (LAP) was obtained from Sigma (Cat: 900889) to be used
as the photo-initiator. Recombinant human vascular endothelial growth
factor A (VEGF-A, Bio-Rad, Cat: PHP293) was used for the in vitro
scratch assay on human umbilical vein endothelial cells (HUVECs,
Sigma, Cat: 200P–05 N). For culturing HUVECs, endothelial cell growth
medium was obtained from Lonza (Cat: CC-3124) while Dulbecco’s
phosphate-buffered saline (DPBS, Gibco) was purchased from Thermo
Fisher Scientific. Matrigel was obtained from Fisher Scientific (Corning,
Cat: CB40234) and used in the scratch assay. Rhodamine B (Rho-B,
Sigma, Cat: R6626) and bovine serum albumin fluorescein isothiocya
nate conjugate (BSA-FITC, Sigma, Cat: A9771) were implemented for
assessment of release profile. Polydimethylsiloxane (PDMS) was pur
chased from Fisher Scientific (Sylgard 184, Cat: NC9285739).

4.5. Assessment of adhesion of in situ printed scaffolds
For evaluating adhesion strength of GelMA to pig skin, a shear test
was performed based on ASTM F2255-05 standard [76]. A rectangular
piece of pig skin (10 mm × 20 mm) was cut and glued to a coverslip
using cyanoacrylate adhesive. Then GelMA was printed on the pig skin,
a charged glass slide was placed on top of it, and GelMA was crosslinked
for 20 s. As shown in Fig. 2B, the sample was then secured on the me
chanical testing device using grips and pulled in shear at a rate of 0.1
mm/s until failure occurred.

4.2. Development and characterization of handheld bioprinter
The developed handheld printer was a miniaturized controllable
syringe pump with embedded curing light [75]. A custom designed
housing was designed in SolidWorks (Dassault Systèmes) and con
structed using stereolithography in a Connex3 Object500 (Stratasys).

4.6. Scanning electron microscopy
For scanning electron microscopy (SEM) analysis, 9% (w/v) GelMA
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hydrogel was printed on a cut piece of pig skin and photo-crosslinked for
20 s. The sample was then dropped into a liquid nitrogen bath to snap
freeze the hydrogel and was immediately placed inside a freeze dryer
(FreeZone 2.5 L − 50C Benchtop, Labconco) to lyophilize for 24 h. The
sample was then broken to expose the cross-section for imaging the in
ternal structure of the hydrogel. The cross-section was mounted on a
stub and coated with gold using a sputter coater device (Vacuum Desk V,
Denton) for 60 s at 20 mA. A benchtop SEM (TM-1000, HITACHI) was
then used to capture the images.

4.10. Animal study
The procedures were performed at Toxikon Corporation (Bedford,
MA). The study protocol was approved by Toxikon’s Institutional Ani
mal Care and Use Committee, and conformed to federal animal laws and
regulations (Project ID number 19-04108-N2). Three Yorkshire pigs
(Animal Biotech Industries, Danboro, PA) weighing between 70 and 80
kg were used in the study. Anesthesia was induced with intramuscular
administration of 3.3 mg/kg ketamine, 1.1 mg/kg acepromazine, 2.2
mg/kg xylazine and 0.02 mg/kg atropine. General anesthesia was
maintained with 0–5% isoflurane and oxygen. After the procedure, a
transdermal patch releasing 2–3 mkg/kg/h fentanyl per hour for 72 h
(Duralgesic, Janssen) was given for pain management during surgical
recovery and buprenorphine 0.01–0.03 mg/kg was administered IM
immediately at the end of the procedure.
Circular full-thickness wounds (d = 1 inch) were created on the
dorsum of each pig using sterile scalpel [60]. After marking the wounds
in parallel paraspinal stripes, the outlines were tattooed with red ink
using an electric tattoo marker (Spaulding & Rogers Manaufacturing
Inc., Voorheesville, NY). Full-thickness wounds down to fascia were
excised. Wounds were separated by at least 4 cm of unwounded skin.
After wound creation, the wounds were randomly divided into 4 treat
ment groups (n = 6): 1) In situ printed GelMA scaffolds containing VEGF;
2) in situ printed GelMA scaffolds without VEGF; 3) topical delivery of
VEGF in PBS, and 4) non-treated (negative control). For all treatment
groups, 1 ml of the therapeutic was administrated. The therapeutic was
GelMA 9%, GelMA 9% supplemented with 400 ng/ml VEGF, and PBS
supplemented with 400 ng/ml VEGF, respectively for groups 1 to 3. We
have previously verified this VEGF dosage required for induction of
endothelial cell migration and consequent vascularization in vitro and in
vivo [4,60]. We have been previously demonstrated that administration
of 100 μL VEGF (500 ng/mL) solution at two time points throughout the
healing process can accelerate the wound (1 cm2) healing in mice, while
400 μL VEGF at the same concentration and administration frequency
can improve porcine wound (5 cm2) healing. A similar dosage was used
in this study for porcine wound healing. For in vivo printing groups
(groups 1 and 2), the printing followed a spiral pattern to fill the entire
wound bed. Subsequently all the wounds were covered independently
with a semipermeable film dressing (Tegaderm, 3 M, Saint Paul, MN).
On day 7 post operatively, the dressings were changed. On postoperative
day 14, the animals were euthanized and the wounds were photo
graphed and harvested for histology. A 14-day long experiment was
designed for this study because it has been shown that acute wounds in
healthy young pigs heal very efficiently. Fig. S4 illustrates the workflow
of the animal study.

4.7. Evaluation of VEGF release profile
GelMA precursor (9% w/v) was supplemented with VEGF (400 ng/
ml) and added to 8 μm pore 24-well Falcon® cell culture inserts
(Corning), followed by its crosslinking for 20 s (n = 4). Blank GelMA was
used as the control group in the experiments (n = 4). The inserts were
then placed into 24-well plates containing 600 μL of DPBS per well. The
plates were placed in an incubating shaker (Fisherbrand™, Fisher Sci
entific) at 37 ◦ C. At each time-point, the DPBS solutions were collected
from the wells and replaced with fresh DPBS. After collection, the so
lutions were stored at − 20 ◦ C. The concentrations of VEGF in the solu
tions were measured using an enzyme-linked immunosorbent assay
(ELISA) kit (900-K10, Peprotech) as per manufacturer-recommended
protocol and the signals were measured using a plate reader (Cytation
5, Biotek).
4.8. Western blot
Western blot test was performed using sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE). Samples (30 μL of the
collected samples from day 7 of the release study with 30 μL of 2X
sample buffer per well) were electrophoresed on 4–20% Tris-Glycine
gels (Invitrogen, Carlsbad, CA), followed by electroblotting to a PVDF
membrane. The membrane was then blocked in 5% non-fat dry milk
(Biorad, Hercules, CA) in Tris-buffered saline + 0.05% Tween-20 (TBST)
for 1h at room temperature. Membranes were then probed with antiVEGF antibody (1:600, 19003-1-AP, Thermo Fischer Scientific, Wal
tham, MA) in 3% non-fat dry milk in TBST overnight at 4 ◦ C. After
washing with TBST, membranes were incubated with goat-anti-rabbit
HRP-conjugated secondary antibody (1:10000, MilliporeSigma, Bur
lington, MA) for 1 h in 3% non-fat dry milk in TBST at room tempera
ture, washed in TBST again, then imaged on a G:Box Chemi XX9 imager
(Syngene, Frederick, MD) using SuperSignal West Femto (Thermo Fisher
Scientific, Waltham, MA).
4.9. In vitro scratch assay

4.10.1. Macroscopic wound closure
The wounds were photographed on day 0 after wound creation, on
day 7 during dressing changes and on day 14 after euthanasia. Macro
scopic wound closure was also calculated from the photos using Image J
software (NIH, Bethesda, MD). The area of the remaining open wound
was measured and compared to the wound area at day 0 and expressed
as a percentage of its original size. Wound contraction was measured of
the tattooed margins from macroscopic wound photos using Image J
software (NIH). The area inside the tattooed line was measured and
expressed as a percentage of its original size on day 0 [78–80].

A scratch assay was performed to evaluate the effect of VEGF
released from the GelMA scaffold on the functionality of the endothelial
cells (Fig. 3A). HUVECs were subcultured up to passage 4 by detaching
the cells using Trypsin-EDTA (Gibco) and resuspending in growth me
dium. A 12-well plate was coated with 5% (v/v) Matrigel overnight,
washed with DPBS, and then seeded with HUVECs at a concentration of
1 × 105 cell/well. Upon HUVECs confluency, a 200 μL pipette tip was
used to gently scratch the confluent HUVECs layer and make a ~350 μm
gap in the cell monolayer.
Following the induction of the scratch, different treatment condi
tions were used: (i) cell culture inserts without a filling reagent (negative
control), (ii) cell culture inserts filled with 200 μL of pure GelMA, (iii)
cell culture inserts filled with 200 μL of GelMA supplemented with 400
ng/ml VEGF, and (iv) cell culture inserts filled with 200 μL of media
supplemented with 400 ng/mL VEGF (positive control). GelMA was
photo-crosslinked for 20 s, and the cell culture inserts were place inside
the cell-seeded wells containing growth media and imaged every 2 h to
monitor the gap closure. The gap area was then measured using FIJI
open-source software and normalized to the initial gap area [77].

4.10.2. Microscopic evaluation
The excised wounds were fixed in formalin, embedded in paraffin,
cut in sections to give a cross section view of the wound edge-to-edge
and stained with hematoxylin and eosion (H&E). The slides were
analyzed for inflammatory infiltrate using the following score scale: 4 =
marked, 3 = moderate, 2 = minimal, and 1 = absent. The amount of
granulation tissue was measured from the total wound area at day 14.
Re-epithelialization was quantified as the area of the new epithelium
divided by the wound area. The degree of scar hypertrophy was
305

K. Nuutila et al.

Bioactive Materials 8 (2022) 296–308
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calculated using scar elevation index (SEI) that represents the ratio of
the total wound area tissue height to the area of normal tissue below the
hypertrophic scar. A SEI of 1 represents no scarring while higher number
represents increased scarring. Epidermal thickness was measured in 5
representative areas of neoepidermis for each wound cross-section. The
number of rete ridges per millimeter of neoepithelium was counted
under the microscope from 5 standardized locations in each wound after
14 days of healing. All the analyses were performed in a blinded fashion.
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4.10.3. Immunohistochemistry staining
The fixed and paraffin embedded tissues were cut in sections to give a
cross section view of the wound edge-to-edge. The wound sections were
immunostained for von Willebrand Factor (vWF; 0082, Dako), based on
manufacturers’ protocols and imaged using a light microscope. The
amount of positive staining was quantified in a blinded-manner in Image
J software.

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.bioactmat.2021.06.030.

4.11. Statistical analyses
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1

Figure S1. The printed filaments using different concentrations of the bioink. A 6% GelMA was
not enough viscous to be compatible for our in situ printing strategy, while a 12% GelMA could
rapidly become gel in room temperature and prevent formation of a smooth filament. A 9%
GelMA was easily printable using our in situ printing strategy. Scale bar is 3 mm.

Figure S2. SEM analysis of the hydrogel internal structure upon critical point drying.

2

Figure S3. Western blot analysis of the VEGF sample collected on day 7 of the release study. The
apparent molecular weight (~30 kDa) of the released VEGF from the hydrogel being consistent
with the value provided by the manufacturer confirms that the majority of the protein remains
intact after 7 days of incubation at 37°C. R1 and R2 shows duplicate samples from the release
study.

Figure S4. The workflow of animal studies in this work. At day 0, circular wounds were created
on the dorsum of the pigs, followed by tattooing the wound border to track the contraction of the
wounds. Photographs were taken, treatments were applied and wounds were covered with
Tagederm dressings to prevent infection. On day 7, the dressing were removed, photographs were
taken and new dressing were attached. Finally, on day 14, the dressings were removed,
photographs were taken and animals were sacrificed. The tissues were harvested and fixed for
analyses.

3

Figure S5. The measurement of the scar evaluation index (SEI) on day 14 post wound creation.
The SEI is the ratio of total wound are tissue height (S1+S2) to the area of normal tissue below the
elevated area due to scarring (S2).

Figure S6. Immunohistological analysis of the wound bed to assess the level of immune response
to the applied treatments on day 14 post surgery. The wound bed was examined for the expression of
cluster of differentiation 3 (CD3), a protein highly expressed on the T-cells. (A) Representative images of
wound bed immune cell infiltration in non-treated wounds compared to those treated with BPS containing
VEGF administrated topically, in vivo printed blank GelMA (GelMA), and in vivo printed GelMA
containing VEGF (GelMA+VEGF). The brown color indicates the presence of CD3. (B) Quantitative
results of immune response to the various treatment methods applied in this work (n=6).
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